Diagnostic performance of circulating exosomes in human cancer: A meta-analysis

Dongming Guo1,2 | Jinpeng Yuan1 | Aosi Xie1 | Zeyin Lin3 | Xinxin Li1 | Juntian Chen1

1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
2Shantou University Medical College, Shantou, China
3Department of Ultrasound, The First Affiliated Hospital of Shantou University Medical College, Shantou, China

Correspondence
Juntian Chen and Xinxin Li, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Shantou University Medical College, No. 57 Changping Road, Shantou 515000, Guangdong, China.
Email: 13809846668@163.com (J.C.); Email: savageli23@163.com (X.L.)

Abstract

Background: Cancer has become a public health problem with high morbidity and mortality. Recent publications have shown that exosomes can be used as potential diagnostic biomarkers of cancer. However, the diagnostic accuracy and reliability of circulating exosomes remain unclear. The present meta-analysis was conducted to comprehensively summarize the overall diagnostic performance of circulating exosomes for cancer.

Methods: Eligible studies published up to June 27, 2019, on PubMed, Embase, and Cochrane Library were selected for the meta-analysis. All statistical analyses were performed by STATA 15.1 statistical software and Meta-DiSc 1.4. Quality Assessment for Studies of Diagnostic Accuracy 2 tool was used to access the quality of included studies. A bivariate mixed-effects model was applied to calculate the diagnostic indexes from included studies.

Results: A total of 5924 participants comprising 3161 cases and 2763 controls from 42 eligible studies were analyzed. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and the area under the curve with 95% confidence intervals (95% CI) were as follows: 0.79 (0.75-0.82), 0.81 (0.78-0.84), 4.1 (3.5-4.8), 0.26 (0.22-0.31), 16 (12-21), and 0.87 (0.84-0.89), respectively. Sensitivity analysis suggested no study exclusively contributed to the heterogeneity, and Deeks’ funnel plot asymmetry test indicated no potential publication bias (P = .09).

Conclusions: The meta-analysis indicated that circulating exosomes could serve as effective and minimally invasive biomarkers for diagnosis of cancer, especially in patients with hepatocellular carcinoma or ovarian cancer, serum-based samples and exosomal proteins.

KEYWORDS
cancer, carcinoma, circulating, diagnosis, exosome, meta-analysis
1 | INTRODUCTION

Cancer is one of the most common diseases and has become a serious public health problem worldwide. In the United States, 1735350 new cancer cases and 609640 cancer deaths are estimated to occur in 2018.1 In China, it is estimated that there will be about 12000 new cancer diagnoses and over 7500 cancer deaths on average each day in 2015.2 One of the important reasons for high mortality and morbidity is the lack of effective screening and detection methods. Currently, traditional tumor markers such as carcinoembryonic antigen, carbohydrate antigen 199 and carbohydrate antigen 125 (CA125), are widely used in clinical practice, but their sensitivity (SEN) and specificity (SPE) are unsatisfied.3,5 Therefore, identifying potential biomarkers for early detection and diagnosis of cancer is urgently needed.

Exosomes are small 40-100 nm vesicles delivered by many cells of the organism, including cancer cells.6 They can be found in all body fluids and play a key role in intercellular communication, which provide information on various different cellular functions and disease states where they can constitute valuable biomarkers.6,7 Tumor-derived exosomes transfer messages from tumor cells to tumor stroma, premetastatic niche, hematopoietic system, and non-cancer stem cells by cancer-initiating cells.8 They contain abundant different types of proteins, nucleic acids, and lipids, which act important roles in tumorigenesis, growth, progression, metastasis, immune escape, and drug resistance as well as treatment of cancer.9 Owing to their enriched contents and excellent stability, exosomes are suggested to be optimal non-invasive biomarkers for cancer diagnosis.10 Increasing studies have shown that exosomes are considered to be a promising diagnostic biomarkers for various types of cancer.11,12 However, due to small sample sizes and various exosomal marker types, there is still heterogeneity or inconsistency in the diagnostic accuracy of exosomes. Thus, we performed the meta-analysis to precisely assess the overall diagnostic accuracy of circulating exosomes in human cancer.

2 | MATERIALS AND METHODS

2.1 | Search strategy

A comprehensive and systematic search was conducted in PubMed, Embase, and Cochrane Library up to June 27, 2019. Search terms were as follows: (cancer OR carcinoma OR tumor OR tumour OR neoplasm) AND (circulating OR serum OR plasma OR blood) AND (exosome OR exosomes OR exosomal) AND (diagnosis OR diagnostic OR sensitivity OR specificity OR "receiver operating characteristic curve" OR ROC). The literature search was performed independently by two authors (DMG and JPY). Any disagreements between the two authors were resolved by discussion with a third author (JTC).

2.2 | Inclusion and exclusion criteria

The inclusion criteria for literature were as follows: (a) studies investigated diagnostic value of exosomal markers for any type of human cancers; (b) exosomes were isolated from serum or plasma; (c) studies included cancer cases and benign or healthy controls; and (d) studies provided sufficient data to construct a diagnostic 2 × 2 table. The exclusion criteria included the following: (a) studies that did not relate to exosomes or cancer; (b) studies that were duplicate articles, reviews, animal studies, editorials, case reports, comments, method articles, expert opinions, conference abstracts, and meta-analyses; (c) studies with at least 20 cases and 20 controls; (d) studies without complete data; (e) studies with no difference in expression of markers; and (f) studies that were not published in English.

2.3 | Data extraction and quality assessment

Information from eligible literatures was independently extracted by two investigators (DMG and JPY). The following data from included studies were collected: first author, publication year, country, exosomal biomarker type, cancer type, sample type, isolation methods, number of case and control, and diagnostic value, including SEN, SPE, true-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN). The quality of each study was assessed independently by two authors (DMG and JPY) using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2),13 which consists of four domains: patient selection, index test, reference standard, and flow and timing. Any discrepancies between the two authors were resolved by a third author (XXL).

2.4 | Statistical analysis

The meta-analysis was conducted by RevMan5.3, Meta-Disc 1.4, and STATA 15.1 software. The heterogeneity of the study was estimated by the Cochran’s Q test and I² index.14 P < .05 for Q test or I² > 50% indicated the existence of heterogeneity. A bivariate mixed-effects model was used to calculate the pooled SEN, SPE, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) with 95% confidence intervals (95% CI). Summary receiver operator characteristic (SROC) curve and forest plots of pooled SEN and SPE were applied to evaluate the diagnostic performance of circulating exosomes. Spearman’s correlation coefficient and ROC plane were used to assess the heterogeneity generated by diagnostic threshold effect. Meta-regression and subgroup analysis were performed to investigate the heterogeneity generated by non-threshold effect. In addition, a bivariate box plot was used to evaluate the potential source of heterogeneity within the selected studies. The clinical practicality of circulating exosomes was examined by Fagan’s nomogram. Moreover, sensitivity analysis and Deeks’ funnel plot asymmetry test were constructed to test the stability of pooled HR and publication bias, respectively.
3 | RESULTS

3.1 | Search results

The flow diagram of article selection is presented in Figure 1A. A total of 3334 literatures were searched from PubMed, Embase, and Cochrane Library. After removing 865 duplicate publications, 2469 articles were included for further assessing. After screening of the title and abstract, 2342 articles were excluded and the remaining 127 literatures were further evaluated. After detailed evaluation of the full texts, 85 articles were excluded for the following reasons: (a) 34 studies not for diagnostic research; (b) 34 studies with insufficient data; (c) 7 studies based on combined diagnosis; (d) 1 study with no difference in expression; (e) 6 studies with sample size less than 20 in either case or control group; and (f) 3 studies with non-English full-text. Finally, a total of 70 studies from 42 publications involving 3161 cases and 2763 controls were analyzed in the meta-analysis.

3.2 | Study characteristics and quality assessments

The main characteristics of included articles are provided in Table 1. All cancer cases were confirmed pathologically. There were fifteen cancer types: lung cancer (LC, n = 7),15-21 esophageal cancer (EC, n = 1),22 gastric cancer (GC, n = 5),23-27 colorectal cancer (CRC, n = 5),28-32 hepatocellular carcinoma (HCC, n = 4),33-36 pancreatic cancer (PC, n = 3),37-39 ovarian cancer (OC, n = 3),40-42 glioma (n = 3),43-45 clear cell renal cell carcinoma (ccRCC, n = 2),50,51 bladder cancer (BC, n = 3),46,48,49 prostate cancer (PCa, n = 2),47,52 osteosarcoma (n = 1),53 multiple myeloma (MM, n = 1),54 melanoma (n = 1),55 and laryngeal squamous cell carcinoma (LSCC, n = 1).56 Publication years of all included researches range from 2013 to 2019. Fifty-nine studies were based on serum and eleven studies based on plasma. The sample sizes of the studies ranged from 40 to 468, and 35 studies included at least 110 participants. Of the seventy studies, thirty studies focused on microRNAs (miRNAs), twenty-two studies focused on long non-coding RNAs (lncRNAs), twelve studies focused on proteins, and six studies focused on other markers (circular RNA, messenger RNA, and small non-coding RNA). The results of study quality assessment were evaluated using QUADAS-2 (Figure 1B and Figure S1). Most studies had low or unclear risks of bias on patient selection, index text, reference standard, and flow and timing, indicating that the quality of included studies was medium.

3.3 | Diagnostic accuracy

Threshold and non-threshold effects are sources of heterogeneity on diagnostic tests. Heterogeneity caused by non-threshold effects was evaluated using Q tests and I-squared. The pooled SEN ($I^2 = 86.81\%, P < .01$) and specificity ($I^2 = 77.27\%, P < .01$) revealed significant heterogeneity (Figure 2). We conducted Spearman’s correlation coefficient and ROC plane to identify heterogeneity

---

**FIGURE 1** Flow diagram of studies’ selection and quality assessment of the included articles
| Author                | Year | Country | Exosomal markers | Cancer type | Specimen | Isolation method | Case | Control | TP | FP | FN | TN |
|-----------------------|------|---------|------------------|-------------|----------|------------------|------|---------|----|----|----|----|
| Wang et al            | 2018 | China   | Protein          | LC          | Serum    | Ultracentrifugation | 183  | 90      | 119| 22| 64 | 68 |
| Zhang et al           | 2019 | China   | miRNA            | LC          | Serum    | Isolation kit     | 100  | 90      | 70 | 16| 30 | 74 |
| Sandfeld-Paulsen et al| 2016 | Denmark | Protein          | LC          | Plasma   | Ultracentrifugation | 57   | 126     | 34 | 31| 23 | 95 |
| Teng et al            | 2019 | China   | LncRNA           | LC          | Plasma   | Ultracentrifugation | 75   | 79      | 57 | 21| 18 | 58 |
| Zhang et al           | 2017 | China   | LncRNA           | LC          | Serum    | Isolation kit     | 77   | 30      | 46 | 6 | 31 | 24 |
| Li et al              | 2019 | China   | LncRNA           | LC          | Serum    | Isolation kit     | 64   | 40      | 55 | 12| 9  | 28 |
| Niu et al             | 2019 | China   | Protein          | LC          | Serum    | Ultracentrifugation | 122  | 46      | 67 | 7 | 55 | 39 |
| Zhao et al            | 2019 | China   | Protein          | ESCC        | Serum    | Isolation kit     | 100  | 100     | 75 | 15| 25 | 85 |
| Yang et al            | 2018 | China   | miRNA            | GC          | Serum    | Isolation kit     | 80   | 80      | 65 | 34| 15 | 46 |
| Zhao et al            | 2018 | China   | LncRNA           | GC          | Serum    | Ultracentrifugation | 126  | 120     | 88 | 18| 38 | 102|
| Pan et al             | 2017 | China   | LncRNA           | GC          | Serum    | Ultracentrifugation | 40   | 37      | 32 | 9 | 8  | 28 |
| Lin et al             | 2018 | China   | LncRNA           | GC          | Plasma   | Ultracentrifugation | 51   | 60      | 45 | 10| 6  | 50 |
| Rahbari et al         | 2019 | Germany | Protein          | GC          | Serum    | Isolation kit     | 49   | 56      | 42 | 14| 7  | 42 |
| Babbagallo et al      | 2018 | Italy   | LncRNA           | CRC         | Serum    | Isolation kit     | 20   | 20      | 20 | 11| 0  | 9  |
| Liu et al             | 2016 | China   | LncRNA           | CRC         | Serum    | Isolation kit     | 20   | 20      | 20 | 11| 0  | 9  |
| Liu et al             | 2018 | China   | miRNA            | CRC         | Plasma   | Ultracentrifugation | 148  | 320     | 104| 18| 44 | 302|
| Liu et al             | 2018 | China   | miRNA            | CRC         | Plasma   | Isolation kit     | 80   | 40      | 64 | 9 | 16 | 31 |
| Liu et al             | 2018 | China   | miRNA            | CRC         | Plasma   | Isolation kit     | 80   | 40      | 56 | 8 | 24 | 32 |
| Sun et al             | 2019 | China   | Protein          | CRC         | Plasma   | Ultracentrifugation | 92   | 32      | 62 | 5 | 30 | 27 |
| Abd El Gwad et al     | 2018 | Egypt   | LncRNA           | HCC         | Serum    | Isolation kit     | 60   | 60      | 58 | 3 | 2  | 57 |
| Abd El Gwad et al     | 2018 | Egypt   | LncRNA           | HCC         | Serum    | Isolation kit     | 60   | 60      | 57 | 12| 3  | 48 |
| Abd El Gwad et al     | 2018 | Egypt   | miRNA            | HCC         | Serum    | Isolation kit     | 60   | 60      | 45 | 16| 15 | 44 |
| Xu et al              | 2018 | China   | miRNA            | HCC         | Serum    | Isolation kit     | 88   | 68      | 75 | 16| 13 | 52 |
| Wang et al            | 2018 | China   | miRNA            | HCC         | Serum    | Ultracentrifugation | 50   | 50      | 50 | 4 | 0  | 46 |
| Xu et al              | 2018 | China   | LncRNA           | HCC         | Serum    | Isolation kit     | 60   | 96      | 43 | 17| 17 | 80 |
| Xu et al              | 2018 | China   | LncRNA           | HCC         | Serum    | Isolation kit     | 55   | 60      | 40 | 12| 15 | 48 |
| Xu et al              | 2018 | China   | LncRNA           | HCC         | Serum    | Isolation kit     | 60   | 96      | 46 | 21| 14 | 75 |
| Que et al             | 2013 | China   | miRNA            | PC          | Serum    | Ultracentrifugation | 22   | 27      | 16 | 2 | 6  | 25 |
| Que et al             | 2013 | China   | miRNA            | PC          | Serum    | Ultracentrifugation | 22   | 27      | 21 | 5 | 1  | 22 |
| Author          | Year | Country | Exosomal markers | Cancer type | Specimen | Isolation method     | Case | Control | TP   | FP  | FN  | TN  |
|-----------------|------|---------|------------------|-------------|----------|----------------------|------|---------|------|-----|-----|-----|
| Goto et al      | 2018 | Japan   | miRNA            | PC          | Serum    | Isolation kit        | 32   | 22      | 23   | 3   | 9   | 19  |
| Melo et al      | 2015 | USA     | Protein          | PC          | Serum    | Ultracentrifugation  | 190  | 126     | 190  | 0   | 0   | 126 |
| Meng et al      | 2016 | Germany | miRNA            | OC          | Serum    | Isolation kit        | 112  | 20      | 94   | 2   | 18  | 18  |
| Kim et al       | 2019 | Korea   | miRNA            | OC          | Serum    | Isolation kit        | 48   | 20      | 44   | 5   | 4   | 15  |
| Su et al        | 2019 | China   | miRNA            | OC          | Serum    | Isolation kit        | 50   | 65      | 31   | 8   | 19  | 57  |
| Santangelo et al| 2018 | Italy   | miRNA            | Glioma      | Serum    | Isolation kit        | 60   | 30      | 49   | 7   | 11  | 23  |
| Shao et al      | 2019 | China   | miRNA            | Glioma      | Serum    | Isolation kit        | 24   | 24      | 19   | 2   | 5   | 22  |
| Manterola et al | 2014 | Spain   | sncRNA           | Glioma      | Serum    | Isolation kit        | 50   | 30      | 33   | 10  | 17  | 20  |
| Zhang et al     | 2018 | China   | miRNA            | ccRCC       | Serum    | Isolation kit        | 82   | 80      | 57   | 10  | 30  | 25  |
| Wang et al      | 2018 | China   | LncRNA           | BC          | Serum    | Isolation kit        | 52   | 104     | 39   | 23  | 13  | 81  |
| Li et al        | 2018 | China   | Protein          | PCa         | Serum    | Ultracentrifugation  | 50   | 21      | 44   | 4   | 6   | 17  |
| Zheng et al     | 2018 | China   | LncRNA           | BC          | Plasma   | Isolation kit        | 50   | 60      | 33   | 9   | 17  | 51  |
| Xue et al       | 2017 | China   | LncRNA           | BC          | Serum    | Isolation kit        | 30   | 30      | 24   | 5   | 6   | 25  |
| Zhang et al     | 2018 | China   | miRNA            | ccRCC       | Serum    | Isolation kit        | 82   | 80      | 57   | 10  | 30  | 25  |
| Wang et al      | 2019 | China   | miRNA            | ccRCC       | Serum    | Isolation kit        | 40   | 30      | 33   | 6   | 7   | 24  |
| Wang et al      | 2018 | China   | LncRNA           | PCa         | Plasma   | Isolation kit        | 34   | 30      | 21   | 5   | 13  | 25  |
| Yuan et al      | 2019 | China   | LncRNA           | Osteosarcoma| Serum    | Isolation kit        | 46   | 45      | 40   | 15  | 6   | 30  |
| Sedlarikova et al| 2018 | Czech   | LncRNA           | MM          | Serum    | Isolation kit        | 50   | 30      | 40   | 7   | 10  | 23  |
| Alegre et al    | 2016 | Spain   | Protein          | Melanoma    | Serum    | Isolation kit        | 53   | 25      | 42   | 5   | 11  | 20  |
| Wang et al      | 2014 | China   | miRNA            | LSCC        | Serum    | Isolation kit        | 52   | 49      | 36   | 10  | 10  | 40  |
| Wang et al      | 2018 | China   | LncRNA           | LSCC        | Serum    | Isolation kit        | 52   | 49      | 48   | 9   | 16  | 28  |

Abbreviations: BC, bladder cancer; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; FN, false negatives; FP, false positives; GC, gastric cancer; HCC, hepatocellular carcinoma; LC, lung cancer; LSCC, laryngeal squamous cell carcinoma; MM, multiple myeloma; OC, ovarian cancer; PC, pancreatic cancer; PCa, prostate cancer; TN, true negatives; TP, true positives.
generated by threshold effects. Spearman’s correlation coefficient was 0.200 (P = .097), and ROC plane did not show the typical shoulder arm (Figure 3A), suggesting that no threshold effects were found.

The forest plots showed that pooled SEN and SPE were 0.79 (95% CI: 0.75-0.82) and 0.81 (95% CI: 0.78-0.84), respectively. SROC curve exhibited that the overall AUC was 0.87 (95% CI: 0.84-0.89) (Figure 3B). In addition, the pooled PLR, NLR, and DOR were 4.1 (95% CI: 3.5-4.8), 0.26 (95% CI: 0.22-0.31), and 16 (95% CI: 12-21), respectively. Fagan’s diagram was applied to assess the predictive value on clinical utility. With a pretest probability of 20%, Fagan’s diagram exhibited that the positive posttest probability of accurately diagnosing cancer would increase to 51%, while the negative probability would drop to 6% (Figure 3C).

3.4 | Meta-regression and subgroup analysis

To investigate potential sources of heterogeneity, meta-regression and subgroup analysis were performed based on type of cancer (LC or not, CRC or not, GC or not, HCC or not, OC or not), sample type (serum or plasma), sample size (≥110 or <110), and exosomal markers (miRNA or not, lncRNA or not, protein or not) (Figure 3D). The exact results of meta-regression analysis are presented in Table 2. We found that research country, LC, CRC, HCC, OC, sample type, isolation method, sample size, exosomal miRNAs, exosomal lncRNAs, and exosomal proteins were likely the sources of heterogeneity in sensitivity. We also found that research country, LC, GC, CRC, HCC, sample type, isolation method, sample size, exosomal miRNAs, exosomal lncRNAs, and exosomal proteins might act as sources of heterogeneity in specificity. As shown in bivariate boxplot (Figure 3E), there were 19 studies not located in the boxplot. After removing these studies, the heterogeneity among studies decreased obviously (SEN: $I^2 = 64.28\%$, $P < .01$ and SPE: $I^2 = 36.52\%$, $P = .01$). The results of subgroup analysis are summarized in Table 3. Studies about HCC or OC exhibited larger AUC (0.90, 95% CI: 0.87-0.92 and 0.90, 95% CI: 0.87-0.93, respectively) compared with other cancer types. Studies involving serum presented higher SEN (0.79, 95% CI: 0.75-0.83), SPE (0.82, 95% CI: 0.78-0.83), PLR (4.3, 95% CI: 3.6-5.2), DOR (17, 95% CI: 12-24), and AUC (0.88, 95% CI: 0.84-0.90) than those involving plasma. In addition, exosomal proteins demonstrated superior SEN (0.86, 95% CI: 0.66-0.95), SPE (0.87, 95% CI: 0.78-0.93), and AUC (0.93, 95% CI: 0.90-0.95) compared to exosomal miRNAs or lncRNAs.
3.5 | Sensitivity analysis and publication bias

To further explore the potential heterogeneity from any single study, sensitivity analysis was performed and showed that our results were not significantly affected by removing any study (Figure 4). Deeks’ funnel plot asymmetry test was applied to examine publication bias for studies. As shown in Figure 2F, A P value of .093 (P > .05) suggested no obvious publication bias among these studies.

4 | DISCUSSION

In the last few years, the potential diagnostic significance of circulating exosomes has been intensively investigated in various diseases, especially in the field of cancer research. Several previous meta-analyses have published the diagnostic value of exosomes in cancer. However, Yang et al.11 focused only on exosomal miRNAs in their meta-analysis. Wong et al.12 did not conduct the overall diagnostic value in cancer, and the number of articles included in their meta-analysis was evidently less than ours. Our study, involving 5924 participants (3161 cases and 2763 controls), and 15 types of cancer, is the first study to comprehensively assess overall diagnostic value of circulating exosomes in human cancer through a meta-analysis. The quality assessment of the included studies was conducted, which exhibited moderate quality. The overall pooled SEN, SPE, and AUC were 0.79 (95% CI: 0.75-0.82), 0.81 (95% CI: 0.78-0.84), and 0.87 (95% CI: 0.83-0.89), respectively. These results indicated that circulating exosomes had relatively high diagnostic accuracy for cancer.

There was significant heterogeneity in the meta-analysis. Spearman’s correlation coefficient was 0.200, and ROC plane showed the absence of typical shoulder arm, meaning heterogeneity was not from threshold effects. Meta-regression analysis was performed to identify heterogeneity caused by non-threshold effects. Our analysis showed that the heterogeneity resulted from research country, cancer type, specimen, isolation method, sample size, and type of exosomal marker. Moreover, there were 19 studies that did not locate in bivariate boxplot, suggesting that the results of these studies might be the main sources of heterogeneity.

According to subgroup analysis, HCC and OC demonstrated the largest AUC, implying that detection of circulating exosomes could be a promising approach for diagnosis of HCC and OC. Alpha-fetoprotein (AFP) is the most widely used tumor marker in diagnosis of liver cancer. The meta-analysis of Dai et al.57 reported that the
AUC of AFP for diagnosis HCC was 0.84. Our results showed that the AUC of circulating exosomes was 0.90, suggesting that the diagnostic value of exosomes was superior to AFP. In addition, Liao et al. concluded that the AUC of CA125 was 0.84 for diagnosis of OC after analyzing 19 literatures. In our meta-analysis, the AUC of blood-based exosomes was 0.90, which exhibited higher value than CA125 in distinguishing OC from non-OC. Additionally, among the included studies of HCC or OC, only one study by Wang et al exhibited high risk of bias on index text. Therefore, the results of these studies showing high efficacy for HCC and OC diagnosis are reliable.

The pooled SEN, SPE, PLR, DOR, and AUC of serum-based exosomes were significantly higher than plasma-based exosomes, meaning that serum seemed to be the better specimen for detection. Moreover, the proportion of low-risk bias in study using serum as a sample was higher than those using plasma, which suggested that studies based on serum specimen had superior quality and reliability. Currently, there is no consensus on sample selection for isolating blood exosomes. When preparing serum, additional extracellular vesicles are released by activated platelets during clot formation, which cannot originally represent the pathophysiological status of the circulating blood in patients and may influent exosome isolation. On the contrary, experimental results of exosomes may be affected by anticoagulants when using plasma as sample. For example, heparin and ethylenediaminetetraacetic acid interfere with polymerase chain reaction. Clearly, it is urgent to establish and validate guidelines for preparation of samples for exosome research.

The included studies used two different methods to isolate blood exosomes. The quality of studies with ultracentrifugation method was inferior to those with isolation kit because of the lower percentage of low-risk bias. Studies with ultracentrifugation method displayed higher diagnostic accuracy. Due to fewer included studies using this method in the meta-analysis, more large-sample studies are needed to confirm this finding. Purifying exosomes is a great challenge because their biophysical properties overlap with other secreted cell products. There are different methods of isolating exosomes, including ultracentrifugation, precipitation, immunoaffinity capturing, filtration techniques, and microfluidics, which results in qualitative and quantitative variability in terms of extracting exosomes. Hence, exploring an

### TABLE 2  The results of meta-regression analysis

| Parameter  | Category | N   | SEN (95% CI)         | P    | SPE (95% CI)         | P    |
|------------|----------|-----|----------------------|------|----------------------|------|
| China      | Yes      | 43  | 0.77 (0.73-0.82)     | <.001| 0.80 (0.76-0.83)     | <.001|
|            | No       | 27  | 0.80 (0.75-0.86)     |      | 0.83 (0.79-0.87)     |      |
| LC         | Yes      | 9   | 0.69 (0.58-0.81)     | <.001| 0.78 (0.70-0.86)     | <.001|
|            | No       | 61  | 0.80 (0.76-0.83)     |      | 0.81 (0.78-0.84)     |      |
| GC         | Yes      | 6   | 0.84 (0.74-0.94)     | .10  | 0.74 (0.63-0.85)     | <.001|
|            | No       | 64  | 0.78 (0.74-0.82)     |      | 0.82 (0.79-0.85)     |      |
| CRC        | Yes      | 7   | 0.76 (0.64-0.89)     | .01  | 0.81 (0.72-0.90)     | <.001|
|            | No       | 63  | 0.79 (0.75-0.83)     |      | 0.81 (0.78-0.84)     |      |
| HCC        | Yes      | 10  | 0.87 (0.80-0.93)     | .04  | 0.80 (0.73-0.87)     | <.001|
|            | No       | 60  | 0.77 (0.73-0.81)     |      | 0.81 (0.78-0.84)     |      |
| OC         | Yes      | 7   | 0.63 (0.49-0.78)     | <.001| 0.92 (0.87-0.97)     | .17  |
|            | No       | 63  | 0.80 (0.76-0.83)     |      | 0.80 (0.77-0.83)     |      |
| Serum      | Yes      | 59  | 0.79 (0.75-0.83)     | .01  | 0.82 (0.78-0.85)     | <.001|
|            | No       | 11  | 0.76 (0.66-0.86)     |      | 0.78 (0.71-0.86)     |      |
| Isolation Kit | Yes    | 54  | 0.77 (0.72-0.81)     | <.001| 0.80 (0.76-0.83)     | <.001|
|            | No       | 16  | 0.85 (0.79-0.91)     |      | 0.85 (0.80-0.89)     |      |
| Sample size ≥ 110 | Yes | 35  | 0.76 (0.71-0.81)     | <.001| 0.82 (0.79-0.86)     | <.001|
|            | No       | 35  | 0.81 (0.77-0.86)     |      | 0.79 (0.75-0.84)     |      |
| miRNA      | Yes      | 30  | 0.75 (0.69-0.81)     | <.001| 0.83 (0.78-0.87)     | <.001|
|            | No       | 40  | 0.81 (0.77-0.85)     |      | 0.80 (0.76-0.84)     |      |
| LncRNA     | Yes      | 22  | 0.81 (0.75-0.87)     | <.001| 0.79 (0.74-0.84)     | <.001|
|            | No       | 48  | 0.77 (0.73-0.82)     |      | 0.82 (0.79-0.85)     |      |
| Protein    | Yes      | 12  | 0.82 (0.75-0.90)     | <.01 | 0.85 (0.80-0.91)     | <.001|
|            | No       | 58  | 0.78 (0.74-0.82)     |      | 0.80 (0.77-0.83)     |      |

Abbreviations: CRC, colorectal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; LC, lung cancer; OC, ovarian cancer; SEN, sensitivity; SPE, specificity.
| Subgroup                          | N  | SEN (95% CI)                  | SPE (95% CI)                  | PLR (95% CI)                  | NLR (95% CI)                  | DOR (95% CI)                  | AUC (95% CI)                  |
|----------------------------------|----|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
| Overall                          | 70 | 0.79 (0.75-0.82)             | 0.81 (0.78-0.84)             | 4.1 (3.5-4.8)                | 0.26 (0.22-0.31)             | 16 (12-21)                   | 0.87 (0.84-0.89)             |
| Type of cancer                   |    |                              |                              |                              |                              |                              |                              |
| Lung cancer                      | 9  | 0.69 (0.62-0.75)             | 0.77 (0.73-0.81)             | 3.0 (2.6-3.5)                | 0.40 (0.33-0.49)             | 7 (6-10)                     | 0.80 (0.76-0.83)             |
| Colorectal cancer                | 7  | 0.75 (0.68-0.80)             | 0.81 (0.68-0.90)             | 4.0 (2.3-6.7)                | 0.31 (0.26-0.38)             | 13 (7-23)                    | 0.81 (0.77-0.84)             |
| Gastric cancer                   | 6  | 0.82 (0.75-0.87)             | 0.73 (0.63-0.81)             | 3.1 (2.2-4.2)                | 0.24 (0.18-0.33)             | 13 (8-20)                    | 0.85 (0.82-0.88)             |
| Hepatocellular carcinoma         | 10 | 0.87 (0.78-0.93)             | 0.80 (0.73-0.86)             | 4.5 (3.0-6.7)                | 0.16 (0.09-0.30)             | 28 (11-73)                   | 0.90 (0.87-0.92)             |
| Ovarian cancer                   | 7  | 0.64 (0.45-0.80)             | 0.91 (0.84-0.95)             | 7.1 (4.4-11.3)               | 0.39 (0.24-0.63)             | 18 (10-33)                   | 0.90 (0.87-0.93)             |
| Other cancers                    | 31 | 0.81 (0.75-0.85)             | 0.81 (0.76-0.86)             | 4.3 (3.2-5.9)                | 0.24 (0.17-0.32)             | 18 (10-33)                   | 0.88 (0.85-0.91)             |
| Sample type                      |    |                              |                              |                              |                              |                              |                              |
| Serum                            | 59 | 0.79 (0.75-0.83)             | 0.82 (0.78-0.85)             | 4.3 (3.6-5.2)                | 0.25 (0.21-0.31)             | 17 (12-24)                   | 0.88 (0.84-0.90)             |
| Plasma                           | 11 | 0.75 (0.68-0.81)             | 0.77 (0.72-0.82)             | 3.3 (2.7-4.0)                | 0.32 (0.26-0.41)             | 10 (7-14)                    | 0.83 (0.79-0.86)             |
| Isolation method                 |    |                              |                              |                              |                              |                              |                              |
| Isolation kit                    | 54 | 0.76 (0.73-0.80)             | 0.80 (0.76-0.83)             | 3.8 (3.3-4.4)                | 0.30 (0.26-0.34)             | 13 (10-16)                   | 0.85 (0.82-0.88)             |
| Ultracentrifugation              | 16 | 0.88 (0.74-0.95)             | 0.86 (0.78-0.92)             | 6.3 (3.6-11.2)               | 0.14 (0.06-0.33)             | 46 (11-187)                  | 0.93 (0.90-0.95)             |
| Sample size                      |    |                              |                              |                              |                              |                              |                              |
| ≥110                             | 35 | 0.76 (0.70-0.81)             | 0.83 (0.78-0.86)             | 4.4 (3.4-5.6)                | 0.29 (0.23-0.37)             | 15 (10-23)                   | 0.87 (0.83-0.89)             |
| <110                             | 35 | 0.81 (0.76-0.85)             | 0.79 (0.75-0.82)             | 3.8 (3.2-4.6)                | 0.24 (0.19-0.30)             | 16 (11-23)                   | 0.86 (0.83-0.89)             |
| Exosomal biomarkers              |    |                              |                              |                              |                              |                              |                              |
| miRNA                            | 30 | 0.75 (0.68-0.80)             | 0.83 (0.78-0.87)             | 4.3 (3.4-5.5)                | 0.31 (0.24-0.38)             | 14 (10-20)                   | 0.86 (0.83-0.89)             |
| LncRNA                           | 22 | 0.81 (0.76-0.85)             | 0.79 (0.73-0.83)             | 3.8 (3.1-4.7)                | 0.25 (0.20-0.31)             | 15 (11-21)                   | 0.87 (0.83-0.89)             |
| Protein                          | 12 | 0.86 (0.66-0.95)             | 0.87 (0.78-0.93)             | 6.9 (3.2-14.6)               | 0.16 (0.05-0.46)             | 44 (7-263)                   | 0.93 (0.90-0.95)             |
| Other markers                    | 6  | 0.78 (0.70-0.84)             | 0.70 (0.62-0.78)             | 2.6 (2.0-3.4)                | 0.32 (0.24-0.42)             | 8 (5-13)                     | 0.80 (0.77-0.84)             |

Abbreviations: AUC, area under the curve; DOR, diagnostic odds ratio; NLR, negative likelihood ratio; PLR, positive likelihood ratio; SEN, sensitivity; SPE, specificity.
effective and standard technique of exosome isolation is urgently required. Suitable sample type and effective isolation method for exosomes detection may further improve the value of cancer diagnosis.

Among the various types of exosomal markers, superior SEN, SPE, and AUC were observed in exosomal protein, implying that exosomal proteins were probably the optimal biomarkers. This subgroup analysis, the studies with other exosomal markers exhibited highest quality according to the QUADAS-2. Among other three types of exosomal biomarkers, the overall risks of bias were similar in each group. Owing to the variety of markers and cancer types, more large-scale studies are required to explore a specific type of exosomal biomarker with high diagnostic accuracy for a certain type of cancer.

We used Deeks’ funnel plot to identify publication bias of enrolled studies, which did not show a very good symmetrical shape. Compared with other included studies, two studies deviated obviously from symmetry, suggesting a possible bias. These two studies were from the same article reported by Melo et al. After careful evaluation of this article, we believe that the possible bias was caused by statistical significance, because their studies revealed an AUC of 1.0 with a sensitivity and specificity of 100%. However, the P-value of funnel plot asymmetry test was .093, confirming that significant publication bias did not exist in general.

There were still some limitations that could not be neglected in this meta-analysis. First, most studies were from China, and the results might therefore not be universally applicable. Second, the inclusion of articles published only in English might result in publication bias. Third, there was significant heterogeneity among the included studies. Although we conducted subgroup analysis and meta-regression to explore the sources of heterogeneity, the results did not fully explain the potential heterogeneity. Thus, more well-designed and multicenter studies with larger sample size are needed to provide more valuable evidence.

In summary, the present meta-analysis indicated that circulating exosomes could be used as effective and minimally invasive biomarkers for distinguishing cancer patients from non-cancer individuals. Circulating exosomes showed higher diagnostic accuracy in patients with HCC or OC, serum-based samples, and exosomal proteins.

CONFLICT OF INTEREST
The authors declare that they have no competing interests.

ORCID
Juntian Chen https://orcid.org/0000-0002-3197-9421

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-132.
3. Shinkins B, Nicholson BD, Primrose J, et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLoS ONE. 2017;12(3):e0171810.
4. Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med. 2007;18(3):175-184.
5. Chang CY, Huang SP, Chiu HM, Lee YC, Chen MF, Lin JT. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepatogastroenterology. 2006;53(67):1-4.
6. Simons M, Raposo G. Exosomes-vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21(4):575-581.
7. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics. 2010;73(10):1907-1920.
8. Zoller M. Exosomes in cancer disease. Methods Mol Biol. 2016;1381:111-149.
9. Chen R, Xu X, Tao Y, Qian Z, Yu Y. Exosomes in hepatocellular carcinoma: a new horizon. Cell Commun Signal. 2019;17(1):1.
10. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomic. 2009;6(3):267-283.
11. Yang B, Xiong WY, Hou HJ, et al. Exosomal miRNAs as biomarkers of cancer: a meta-analysis. Clin Lab. 2019;65(5):789-799.
12. Wong CH, Chen YC. Clinical significance of exosomes as potential biomarkers in cancer. World J Clin Cases. 2019;7(2):171-190.
13. Whiting PF, Higgins JP, Rutjes AW, et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):S29-U104.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
15. Wang N, Song X, Liu L, et al. Circulating exosomes contain protein biomarkers of metastatic non-small-cell lung cancer. Cancer Sci. 2018;109(5):1701-1709.
16. Zhang Y, Zhang Y, Yin Y, Li S. Detection of circulating exosomal miR-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients. Pathol Res Pract. 2019;215(8):152466.
17. Sandfeld-Paulsen B, Jakobsen KR, Bæk R, et al. Exosomal proteins as diagnostic biomarkers in lung cancer. J Thorac Oncol. 2016;11(10):1701-1710.
18. Teng Y, Kang H, Chu Y. Identification of an exosomal long non-coding RNA SOX2-OT in plasma as a promising biomarker for lung squamous cell carcinoma. Genet Test Mol Biomarkers. 2019;23(4):235-240.
19. Zhang R, Xia Y, Wang Z, et al. Serum long non coding RNA MALAT-1 protected by exosomes is up-regulated and promotes cell proliferation and migration in non-small cell lung cancer. Biochim Biophys Acta. 2017;1892(2):406-414.
20. Li C, Lv Y, Shao C, et al. Tumor-derived exosomal IncRNA GASS as a biomarker for early-stage non-small-cell lung cancer diagnosis. J Cell Physiol. 2019;234(11):20721-20727.
21. Niu L, Song X, Wang N, Xue L, Song X, Xie L. Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer. Cancer Sci. 2019;110(1):433-442.
22. Zhao A, Guo L, Xu J, et al. Identification and validation of circulating exosomes-based liquid biopsy for esophageal cancer. Cancer Med. 2019;8(7):3566-3574.
23. Yang H, Fu H, Wang B, et al. Exosomal miR-423-5p targets SUFU to promote cancer growth and metastasis and serves as a novel marker for gastric cancer. Mol Carcinog. 2018;57(9):1223-1236.
24. Zhao R, Zhang Y, Zhang X, et al. Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer. Mol Cancer. 2018;17(1):68.
25. Pan L, Liang W, Fu M, et al. Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression. J Cancer Res Clin Oncol. 2017;143(6):991-1004.
26. Lin LY, Yang L, Zeng Q, et al. Tumor-originated exosomal IncUENC1 as a circulating biomarker for early-stage gastric cancer. Mol Cancer. 2018;17(1):84.
27. Rahbari M, Pecqueux M, Aust D, et al. Expression of glypican 3 is an independent prognostic biomarker in primary gastro-esophageal adenocarcinoma and corresponding serum exosomes. J Clin Med. 2019;8(5):696.
28. Barbagallo C, Bred C, Caponnetto A, et al. LncRNA UCA1, upregulated in CRC biopsies and downregulated in serum exosomes, controls mRNA expression by RNA-RNA interactions. Mol Ther Nucleic Acids. 2018;12:229-241.
29. Liu T, Zhang X, Gao S, et al. Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. Oncotarget. 2016;7(51):85551-85563.
30. Liu X, Pan B, Sun L, et al. Circulating exosomal miR-27a and miR-130a act as novel diagnostic and prognostic biomarkers of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2018;27(7):746-754.
31. Liu X, Chen X, Zeng K, et al. DNA-methylation-mediated silencing of miR-486-5p promotes colorectal cancer proliferation and migration through activation of PLAGL2/IGF2/beta-catenin signaling pathways. Cell Death Dis. 2018;9(10):1037.
32. Sun B, Li Y, Zhou Y, et al. Circulating exosomal CPNE3 as a diagnostic and prognostic biomarker for colorectal cancer. J Cell Physiol. 2019;234(2):1416-1425.
33. Abd El Gwad A, Mattoli M, El-Tawdi A, et al. Role of exosomal competing endogenous RNA in patients with hepatocellular carcinoma. J Cell Biochem. 2018;119(10):8600-8610.
34. Xu H, Dong X, Chen Y, Wang X. Serum exosomal hnrRNPH1 mRNA as a novel marker for hepatocellular carcinoma. Clin Chem Lab Med. 2018;56(3):479-484.
35. Wang Y, Zhang C, Zhang P, et al. Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma. Cancer Med. 2018;7(5):1670-1679.
36. Xu H, Chen Y, Dong X. Serum WX. Exosomal Long Noncoding RNAs ENSG00000258332.1 and LINCO0635 for the Diagnosis and Prognosis of Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev. 2018;27(6):710-716.
37. Que R, Ding G, Chen J, Cao L. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. World J Surg Oncol. 2013:11:219.
38. Goto T, Fujiya M, Konishi H, et al. An elevated expression of serum exosomal microRNA-191 - 21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker. BMC Cancer. 2018;18(1):116.
39. Melo SA, Luecke LB, Kahler C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177-182.
40. Meng X, Müller V, Milde-Langosch K, Trllisch F, Pantel K, Schwarzenbach H. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016;7(13):16923-16935.
41. Kim S, Choi MC, Jeong JY, et al. Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas. J Cancer. 2019;10(9):1958-1967.
42. Su YY, Sun L, Guo ZR, et al. Uregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer. J Ovarian Res. 2019;12(1):6.
43. Santangelo A, Imbruce P, Gardenghi B, et al. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. J Neurooncol. 2018;136(1):51-62.
44. Shao N, Xue L, Wang R, Luo K, Zhi F, Lan Q. miR-454-3p is an exosomal biomarker and functions as a tumor suppressor in glioma. Mol Cancer Ther. 2018;18(2):459-469.
45. Manterola L, Guruceaga E, Pérez-Larraya JG, et al. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol. 2014;16(4):520-527.
46. Wang J, Yang Y, Yuan W, Gao Z. Determination of serum exosomal H19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis. Med Sci Monit. 2018;24:9307-9316.
47. Li S, Zhao Y, Chen W, et al. Exosomal ephrinA2 derived from serum as a potential biomarker for prostate cancer. J Cancer. 2018;9(15):2659-2665.
48. Zheng R, Du M, Wang X, et al. Exosome-transmitted long non-coding RNA PTEPN1 suppresses bladder cancer progression. Mol Cancer. 2018;17(1):143.
49. Xue M, Chen W, Xiang A, et al. Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1. Mol Cancer. 2017;16(1):143.
50. Zhang W, Ni M, Su Y, et al. MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. Eur Urol Focus. 2018;4(3):412-419.
51. Wang X, Wang T, Chen C, et al. Serum exosomal miR-210 as a potential biomarker for clear cell renal cell carcinoma. *J Cell Biochem*. 2019;120(2):1492-1502.

52. Wang YH, Ji J, Wang BC, et al. Tumor-derived exosomal long non-coding RNAs as promising diagnostic biomarkers for prostate cancer. *Cell Physiol Biochem*. 2018;46(2):532-545.

53. Yuan TB, Liu J, Chen SC, et al. Clinical significance of exosomal long noncoding RNA DANCR as a novel serum-based diagnostic and prognostic biomarker in osteosarcoma. *Inter J Clin Exp Med*. 2019;12(1):423-432.

54. Sedlarikova L, Bollova B, Radova L, et al. Circulating exosomal long noncoding RNA PRINS—first findings in monoclonal gammopathies. *Hematol Oncol*. 2018;36(5):786-791.

55. Alegre E, Zubiri L, Perez-Gracia JL, et al. Circulating melanoma exosomes as diagnostic and prognosis biomarkers. *Clin Chim Acta*. 2016;454:28-32.

56. Wang J, Zhou Y, Lu J, et al. Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. *Med Oncol*. 2014;31(9):148.

57. Dai M, Chen X, Liu X, Peng Z, Meng J, Dai S. Diagnostic value of the combination of Golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma: a meta-analysis. *PloS ONE*. 2015;10(10):e0140067.

58. Liao XY, Huang GJ, Gao C, Wang GH. A meta-analysis of serum cancer antigen 125 array for diagnosis of ovarian cancer in Chinese. *J Cancer Res Ther*. 2014;10(7):C222-C224.

59. Coumans FAW, Brisson AR, Buzas EI, et al. Methodological guidelines to study extracellular vesicles. *Circ Res*. 2017;120(10):1632-1648.

60. Witwer KW, Buzás EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. *J Extracell Vesicles*. 2013;2. https://doi.org/10.3402/jev.v2i0.20360

61. Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in exosome isolation techniques. *Theranostics*. 2017;7(3):789-804.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Guo D, Yuan J, Xie A, Lin Z, Li X, Chen J. Diagnostic performance of circulating exosomes in human cancer: A meta-analysis. *J Clin Lab Anal*. 2020;34:e23341. [https://doi.org/10.1002/jcla.23341](https://doi.org/10.1002/jcla.23341)